The modified flap reconstruction technique has the potential to be considered reliable for the definitive circumferential reconstruction of extensive laryngotracheal defects not amenable to being cured by conventional techniques.

No abstract

19%:81%. 312 cycles of treatment were administered and 14 patients had dose reductions (26.4%); median number of doses was 5 for both G and P, and median dose intensity was 98.05% for both G and P. Confirmed responses were 0 CRs, 11 PRs, (20.8%), 23 SDs (43.4%), and 14 PDs (26.4%), with a median duration of response of 10.3 mos (95%CI, 3.2, 20.0). Patient-based G3/4 hematologic events included febrile neutropenia (9.4%), neutropenia (28.3%), and thrombocytopenia (5.7%). Grade 3/4 nonhematologic events included fatigue (22.6%), dyspnea (7.5%), dehydration (7.5%), diarrhea (5.7%), constipation (3.8%), nausea (3.8%), ALT elevation (3.8%), and pneumonia (1.9%). Median TTP was 4.6 mos (95%CI, 2.8, 6.2; 30.2% censored) and median OS was 10.1 mos (95%CI, 6.0, 14.1; 41.0% 1-yr survival; 20.8% censored). Conclusion: Biweekly G and P appear to be well tolerated in advanced NSCLC. A median OS of 10.1 mos and clinical benefit rate (ORR + SD) of 64.2% indicates activity in patients with advanced NSCLC. The dose intensity for biweekly G and P is higher than a previously reported 6-cycle, 21-day regimen with median dose intensity of 83.2% for P and 82.2% for G (West, et al. Proc ASCO 2005; 7117).

No abstract

No abstract